Sabadell - Sanofi (SAN) SANOFI: CAÍDAS LIGADAS AL JUICIO POR ZANTAC (ANÁLISIS BANCO SABADELL)

Report

Sabadell

Alvaro del Pozo

EUR 50.00 For Business Accounts Only

SANOFI: CAÍDAS LIGADAS AL JUICIO POR ZANTAC (ANÁLISIS BANCO SABADELL)

El valor cae ahora un -7% vs Euro Stoxx 50, extendiendo hasta un -15% la caída acumulada en las 2 últimas sesiones, por la incertidumbre atribuida al potencial resultado del juicio por Zantac que se espera se celebre en Illinois (EE.UU.) este 22 de agosto. Recordamos que Zantac fue un antiácido popular fabricado por Sanofi, GSK and Boehringer Ingelheim GmbH (además de otros fabricantes genéricos) retirado del mercado en 2019 después de que la US Food and Drug Administration dijera que producía niveles inaceptables de agentes cancerígenos al ser expuesto al calor durante 5 días. SANO por su parte ha venido rebajando los riesgos asociados al litigio, indicando que no hay evidencia fiable de que Zantac pueda causar cancer.

11/08/2022 1 ES

Underlying

Sanofi

Sanofi is an integrated, global healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. Two segments make up Co.'s business: Pharmaceuticals and Vaccines. The Pharmaceuticals segment covers research, development, production and marketing of medicines, consisting of flagship products, plus a broad range of prescription medicines, generic medicines, and consumer health products. The Vaccines segment includes research, development, production and marketing of vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines.

See profile

FR0000120578 Euronext Paris France

Provider

Sabadell

See profile

Analysts

Alvaro del Pozo

Other Reports on these Companies

GlobeNewsWire

Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan

Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan Sanofi Launches 2025 Global Employee Stock Purchase Plan Paris, June 5, 2025. Sanofi’s global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 employees in 55 countries. Now in its 11th year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve employees in the company’s growth and results. In 2024 alone, more than 32,000 Sanofi employees - 40% of the total workforce, chose to invest in the company through the program. Today, nearly 90,000 cu...

June 5, 2025 June 5, 2025 1 EN

GlobeNewsWire

Communiqué de presse : Sanofi lance son plan mondial 2025 d’actionnariat salarié

Communiqué de presse : Sanofi lance son plan mondial 2025 d’actionnariat salarié Sanofi lance son plan mondial 2025 d’actionnariat salarié Paris, le 5 juin 2025. Sanofi lance Action 2025, son plan mondial d’actionnariat salarié, qui sera ouvert le 10 juin 2025 à environ 70 000 salariés dans 55 pays. Ce plan, qui entre dans sa onzième année d’existence, témoigne de la volonté renouvelée de Sanofi et de son Conseil d’administration d’associer les salariés à la croissance et aux résultats de l’entreprise. Rien qu’en 2024, plus de 32 000 salariés de Sanofi – 40% des employés, ont choisi d’i...

June 5, 2025 June 5, 2025 1 EN

GlobeNewsWire

Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector

Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector ASCO: new Sarclisa data support subcutaneous administration with on-body injector New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse® on-body injector, an automated hands-free injectorData will form the basis of global regulatory submissions across all currently approved lines...

June 3, 2025 June 3, 2025 1 EN

IBERIAN DAILY 06 JUNE (ANÁLISIS BANCO SABADELL)

NEWS SUMMARY: ELECTRICITY SECTOR, INDITEX. IBEX reaches 14,200 Stock markets ended stable in a session in which the ECB followed the expected script. In the STOXX 600, the best-performing sectors were cyclicals like Basic Materials and Construction, whereas Consumer Goods and Chemicals ended with the biggest drops. On the macro side, in Germany industrial orders rose unexpectedly in April. In the euro zone, the June ECB meeting brought a -25bps rate cut, as expected, and C. Lagarde suggested the monetary cycle policy would be reaching its end but insisting that they are in a good position to ...

EUR 100.00

June 6, 2025 June 6, 2025 1 EN

Research Department

Research Department

INFORME DIARIO 06 JUNIO (ANÁLISIS BANCO SABADELL)

COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: INDITEX, SECTOR ELÉCTRICO. EUROPA: AIRBUS, KERING. El Ibex alcanza los 14.200 puntos Las bolsas terminaron estables en una sesión en que el BCE cumplió con el guion esperado. En el STOXX 600 los mejores sectores fueron cíclicos como R. Básicos y Construcción, mientras que B. Consumo y Químicas terminaron con las mayores cesiones. Por el lado macro, en Alemania los pedidos industriales sorprendieron avanzando en abril de forma inesperada. En la Eurozona el BCE de junio recortó como se esperaba los tipos de interés en -25 p.b. y C. Lagarde apuntando...

EUR 100.00

June 6, 2025 June 6, 2025 1 ES

Research Department

Research Department

SEMANAL MERCADOS: EL MERCADO SERÁ CADA VEZ MÁS EXIGENTE CON LA DEUDA DE EE.UU. (ANÁLISIS BANCO SABADELL)

Por un lado, la reforma presupuestaria (OBBBA) de D. Trump que intenta aprobar el Senado aumentaría el déficit para los próximos años y además hasta podría impactar negativamente a las compañías europeas con negocios allí a través de la sección 899. Por otro lado, no creemos que los aranceles puedan compensar el mayor déficit de la OBBBA y menos aún reducir el déficit hasta el 4,5% para estabilizar la deuda a largo plazo. Por eso el mercado seguirá aumentando gradualmente la prima (a plazo) exigida a EE.UU. lo que incrementa los riesgos de una TIR a 10 años en el 5,0% poniendo en duda la valor...

EUR 100.00

June 5, 2025 June 5, 2025 1 ES

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

SANOFI: CAÍDAS LIGADAS AL JUICIO POR ZANTAC (ANÁLISIS BANCO SABADELL)

Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan

Communiqué de presse : Sanofi lance son plan mondial 2025 d’actionnariat salarié

Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector

IBERIAN DAILY 06 JUNE (ANÁLISIS BANCO SABADELL)

INFORME DIARIO 06 JUNIO (ANÁLISIS BANCO SABADELL)

SEMANAL MERCADOS: EL MERCADO SERÁ CADA VEZ MÁS EXIGENTE CON LA DEUDA DE EE.UU. (ANÁLISIS BANCO SABADELL)

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe